{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:44:38Z","timestamp":1759452278363,"version":"build-2065373602"},"reference-count":16,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The impact of the COVID\u201019 pandemic on patients with inflammatory rheumatic diseases, such as ankylosing spondylitis (AS), has been variable. Here, we assess disease activity and health\u2010related quality of life (HRQoL) through the pandemic in patients with AS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the open\u2010label extension (OLE) of the phase 2b BE AGILE study, patients with AS received 160 mg of subcutaneous bimekizumab every 4\u2009weeks. We assessed Ankylosing Spondylitis Disease Activity Score with C\u2010reactive protein (ASDAS\u2010CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Quality of Life (ASQoL) scores in the OLE immediately before and during the COVID\u201019 pandemic (September 2019 to April 2021).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 232 patients remained in the BE AGILE OLE and were included in this post hoc study at the start of the analysis period (September 1, 2019); 12 patients had a COVID\u201019 treatment\u2010emergent adverse event, and no cases resulted in death. The number of missed bimekizumab doses due to COVID\u201019 (11 doses) was minimal, and missed assessments remained low (\u22645%) compared with the prepandemic period. Mean ASDAS\u2010CRP (1.8), BASDAI (2.4), and ASQoL scores (2.8) in the OLE were low at pre\u2010pandemic baseline and remained stable at 1.7 to 1.8, 2.2 to 2.4, and 2.0 to 2.8, respectively, across successive 3\u2010month periods immediately before and during the pandemic. ASDAS\u2010CRP, BASDAI, and ASQoL stability was consistent across major study countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Disease activity and HRQoL remained stable during the COVID\u201019 pandemic in patients with AS receiving bimekizumab in the BE AGILE OLE, with no indication of negative effects on these outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11486","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T06:46:29Z","timestamp":1657781189000},"page":"819-824","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimal Impact of the <scp>COVID<\/scp>\u201019 Pandemic on Disease Activity and <scp>Health\u2010Related<\/scp> Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b <scp>Open\u2010Label<\/scp> Extension Study"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C.","family":"Robinson","sequence":"first","affiliation":[{"name":"University of Queensland School of Clinical Medicine  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-4771","authenticated-orcid":false,"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital, University of Toronto and Schroeder Arthritis Institute  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-5336","authenticated-orcid":false,"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[{"name":"University California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-0913","authenticated-orcid":false,"given":"John D.","family":"Reveille","sequence":"additional","affiliation":[{"name":"The University of Texas McGovern Medical School  Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma  Colombes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vaux","sequence":"additional","affiliation":[{"name":"UCB Pharma  Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fleurinck","sequence":"additional","affiliation":[{"name":"UCB Pharma  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marga","family":"Oortgiesen","sequence":"additional","affiliation":[{"name":"UCB Pharma  Raleigh North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"de Peyrecave","sequence":"additional","affiliation":[{"name":"UCB Pharma  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University  Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091793"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1784-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4054"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11174"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218705"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001546"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab174"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04863-x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220584"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04952-x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"issue":"10","key":"e_1_2_8_13_1","article-title":"Bimekizumab long\u2010term efficacy and safety over 96\u2009weeks in patients with ankylosing spondylitis: interim results from a phase 2b open\u2010label extension study [abstract]","volume":"72","author":"Baraliakos X","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.156"},{"key":"e_1_2_8_15_1","unstructured":"World Health Organization.WHO Director\u2010General's opening remarks at the media briefing on COVID\u201019 \u2013 11 March 2020. URL:https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"issue":"10","key":"e_1_2_8_16_1","article-title":"Bimekizumab long\u2010term safety and efficacy in patients with ankylosing spondylitis: interim results after 3\u2009years of treatment in an ongoing phase 2b study [abstract]","volume":"73","author":"Gensler LS","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00175-2"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11486","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:35:11Z","timestamp":1759415711000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/acr2.11486"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11486","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"type":"print","value":"2578-5745"},{"type":"electronic","value":"2578-5745"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"2022-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}